[go: up one dir, main page]

WO2006017171A3 - Methods of diagnosing & treating obesity, diabetes and insulin resistance - Google Patents

Methods of diagnosing & treating obesity, diabetes and insulin resistance Download PDF

Info

Publication number
WO2006017171A3
WO2006017171A3 PCT/US2005/024256 US2005024256W WO2006017171A3 WO 2006017171 A3 WO2006017171 A3 WO 2006017171A3 US 2005024256 W US2005024256 W US 2005024256W WO 2006017171 A3 WO2006017171 A3 WO 2006017171A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
methods
diagnosing
insulin resistance
treating obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/024256
Other languages
French (fr)
Other versions
WO2006017171A2 (en
Inventor
Shonna A Moodie
Fang Zhang
Paul G Rack
Jin Shang
Daniel M Joo
Chi-Wai Wong
Francine Gregoire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CymaBay Therapeutics Inc
Original Assignee
Metabolex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolex Inc filed Critical Metabolex Inc
Priority to JP2007521515A priority Critical patent/JP2008506949A/en
Publication of WO2006017171A2 publication Critical patent/WO2006017171A2/en
Anticipated expiration legal-status Critical
Publication of WO2006017171A3 publication Critical patent/WO2006017171A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides compositions and methods for diagnosing and treating obesity, diabetes and insulin resistance. In particular, the invention provides methods of identifying modulators of the polynucleotides or polypeptides of the invention and using those modulators to treat obesity and/or diabetes, as well as methods of diagnosing obesity and/or diabetes by measuring the levels of the polynucleotides or polypeptides of the invention in a patient.
PCT/US2005/024256 2004-07-13 2005-07-07 Methods of diagnosing & treating obesity, diabetes and insulin resistance Ceased WO2006017171A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007521515A JP2008506949A (en) 2004-07-13 2005-07-07 Methods for diagnosis and treatment of obesity, diabetes and insulin resistance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58778004P 2004-07-13 2004-07-13
US60/587,780 2004-07-13

Publications (2)

Publication Number Publication Date
WO2006017171A2 WO2006017171A2 (en) 2006-02-16
WO2006017171A3 true WO2006017171A3 (en) 2009-06-11

Family

ID=35839747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/024256 Ceased WO2006017171A2 (en) 2004-07-13 2005-07-07 Methods of diagnosing & treating obesity, diabetes and insulin resistance

Country Status (2)

Country Link
JP (1) JP2008506949A (en)
WO (1) WO2006017171A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040205A1 (en) * 2003-10-28 2005-05-06 Protemix Discovery Limited Peptides with anti-obesity activity and other related uses
US20080200568A1 (en) * 2005-08-30 2008-08-21 Stephanie Chissoe Genes Associated With Type ll Diabetes Mellitus
US7763441B2 (en) 2006-03-13 2010-07-27 Wyeth Modulators of gluconeogenesis
WO2008061902A2 (en) * 2006-11-24 2008-05-29 Vrije Universiteit Brussel Targeting of l-3-hydroxyacyl-coenzyme a dehydrogenase, short chain (hadhsc) in disorders of glucose homeostasis
WO2009057461A1 (en) * 2007-10-31 2009-05-07 Kobe University Therapeutic agent for diabetes
BR112013009196A2 (en) * 2010-10-15 2020-08-25 The Trustees Of Columbia University In The City Of New York uses of polypeptide to reduce fatty acid acquisition and food intake, as well as promoting satiety related to obesity
EP2524927A1 (en) * 2011-05-20 2012-11-21 Covagen AG New chymase binding compounds and medical uses thereof
US11154591B2 (en) 2016-10-14 2021-10-26 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
JP2018068235A (en) * 2016-10-31 2018-05-10 国立大学法人神戸大学 Anti-insulin resistance substance screening method
KR20210006916A (en) * 2018-05-07 2021-01-19 젠와인 바이오테크놀로지 게엠바하 A simple method for purifying lacto-N-neotetraose (LNnT) from carbohydrates obtained by microbial fermentation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028479A2 (en) * 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003082335A1 (en) * 2002-04-03 2005-07-28 住友製薬株式会社 Novel blood glucose regulator and screening method thereof
US6854933B2 (en) * 2002-08-07 2005-02-15 Deepwater Technologies, Inc. Vertically restrained centerwell SPAR
JPWO2004053124A1 (en) * 2002-12-06 2006-04-13 塩野義製薬株式会社 Screening method for therapeutic or preventive agent for diabetes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028479A2 (en) * 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis

Also Published As

Publication number Publication date
WO2006017171A2 (en) 2006-02-16
JP2008506949A (en) 2008-03-06

Similar Documents

Publication Publication Date Title
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2009038689A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2006040129A3 (en) Ubiquitin or gamma-crystalline conjugates for use in therapy, diagnosis and chromatography
TW200608961A (en) Methods and reagents for the treatment of metabolic disorders
IL198922A0 (en) Chemical compounds and uses
WO2008055491A3 (en) Diagnosis and risk assessment of pancreatic diabetes using mr-proadm
WO2004110375A3 (en) Combination therapy for the treatment of diabetes
WO2008036341A3 (en) Compositions and methods relating to glucagon receptor antibodies
WO2006044531A3 (en) Antisense modulation of ptp1b expression
WO2006053043A3 (en) Methods of treating diabetes mellitus
WO2011002834A3 (en) Compositions and methods for diagnosis and treatment of type 1 diabetes
WO2007079171A3 (en) Treatment for hodgkin's lymphoma
WO2009023048A3 (en) Markers for metabolic syndrome
WO2007079146A8 (en) Treatment for non-hodgkin's lymphoma
WO2008008348A3 (en) Method and compositions for treating stroke with fever
WO2006017171A3 (en) Methods of diagnosing & treating obesity, diabetes and insulin resistance
WO2003101284A3 (en) Methods of diagnosing and treating diabetes and insulin resistance
WO2005034737A3 (en) Methods for diagnosing and treating endoplasmic reticulum (er) stress diseases
ATE504595T1 (en) IL-22 FOR THE TREATMENT OF OBESITY, DIABETES, HYPERLIPIDEMIA, HYPERGLYCEMIA AND INSULIN RESISTANCE
WO2006007400A9 (en) Methods of diagnosing and treating obesity, diabetes and insulin resistance
WO2003102161A3 (en) Methods of diagnosing & treating diabetes and insulin resistance
WO2007117794A3 (en) Glycated peptides and methods of use
WO2008059041A3 (en) Complementation of factor xi deficiency by factor v mutants
WO2006010051A3 (en) Methods of diagnosing & treating diabetes and insulin resistance
WO2005124359A3 (en) Methods of diagnosing and treating diabetes and insulin resistance

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007521515

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase